At its Jan. 13 meeting, the Augusta Planning Board tabled Main Street I LLC’s request to convert the Burleigh Building at the Kennebec Arsenal into 15 residential units.
It was the right call. For those of us who have followed debates about this property for nearly 20 years, it is hard to place confidence in yet another proposal from Niemann Capital, LLC and its owner, Tom Niemann.
Back in 2007, the vision included luxury apartments, a boutique hotel, retail shops, restaurants, cafés, a park and a wellness center. None of it materialized.
In July 2022, Niemann shifted to a housing-focused plan, telling Augusta that within “24 months or less” he would redevelop five Arsenal buildings for $1.76 million. He declared, “We’re literally on the verge of becoming a full-fledged construction site.” Again, nothing happened.
The redevelopment of the Kennebec Arsenal has been a failure, and legal disputes with Niemann continue. Augusta cannot afford further missteps with this historic site.
The Planning Board has now asked Niemann to appear at the next meeting and explain to Augusta’s residents why his latest proposal deserves their trust — and how it fits into any credible long-term plan for the property.
Planning Board meetings are held at 6 p.m. the second Tuesday of each month at City Center. Agendas are available at augustamaine.gov/planning-board-materials.
Mary Owen
Augusta
We invite you to add your comments. We encourage a thoughtful exchange of ideas and information on this website. By joining the conversation, you are agreeing to our commenting policy and terms of use. More information is found on our FAQs. You can modify your screen name here.
Comments are managed by our staff during regular business hours Monday through Friday as well as limited hours on Saturday and Sunday. Comments held for moderation outside of those hours may take longer to approve.
Join the Conversation
Please sign into your CentralMaine.com account to participate in conversations below. If you do not have an account, you can register or subscribe. Questions? Please see our FAQs.